Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016523 · ClinicalTrials.gov registry record · Phase 3
Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure
A Phase 3 study, sponsored by NICHD Neonatal Research Network.
- Terminated
- Registry status
- Phase 3
- Development phase
- 420
- Enrollment target
NCT00016523 is a Phase 3 study that was terminated before completion, run by NICHD Neonatal Research Network. The registered enrollment target is 420 participants.
The verdict
NCT00016523, a Phase 3 study, was terminated before completion, sponsored by NICHD Neonatal Research Network.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 420 participants
- Enrollment target
Study Summary
This multicenter trial tested whether inhaled nitric oxide would reduce death or the need for oxygen in preterm infants (less than 34 weeks gestational age) with severe lung disease.
Interventions
- DRUG Placebo
- DRUG Inhaled nitric oxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2001-01 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00016523
The ClinicalTrials.gov registry entry for NCT00016523 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NICHD Neonatal Research Network, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00016523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00016523 about?
NCT00016523 is a clinical study titled "Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure". This multicenter trial tested whether inhaled nitric oxide would reduce death or the need for oxygen in preterm infants (less than 34 weeks gestational age) with severe lung disease.
What is the current status of trial NCT00016523?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 420 participants. The study started on 2001-01. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00016523?
The interventions under investigation include: Placebo (DRUG), Inhaled nitric oxide (DRUG).
Who is sponsoring clinical trial NCT00016523?
This trial is sponsored by NICHD Neonatal Research Network, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.